A first-in-human study of $^{68}$Ga-Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death

Ivan Ho Shon1,2,3 · Thomas Hennessy1 · Jennifer Guille1 · Michael P. Gotsbacher4 · Angelina J. Lay2 · Bruce McBride1 · Rachel Codd4 · Philip J. Hogg2

Received: 6 May 2022 / Accepted: 14 June 2022 / Published online: 2 July 2022 © The Author(s) 2022

Abstract

Purpose This study assesses human biodistribution, radiation dosimetry, safety and tumour uptake of cell death indicator labelled with $^{68}$Ga (Ga-Ga-CDI), a novel radiopharmaceutical that can image multiple forms of cell death.

Methods Five participants with at least one extracranial site of solid malignancy > 2 cm and no active cancer treatment in the 8 weeks prior to the study were enrolled. Participants were administered 205 ± 4.1 MBq (range, 200–211 MBq) of $^{68}$Ga-Ga-CDI and 8 serial PET scans acquired: the first commencing immediately and the last 3 h later. Participants were monitored for clinical, laboratory and electrocardiographic side effects and adverse events. Urine and blood radioactivity was measured. Spherical volumes of interest were drawn over tumour, blood pool and organs to determine biodistribution and calculate dosimetry. In one participant, tumour specimens were analysed for cell death using terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) staining.

Results $^{68}$Ga-Ga-CDI is safe and well-tolerated with no side effects or adverse events. $^{68}$Ga-Ga-CDI is renally excreted, demonstrates low levels of physiologic uptake in the other organs and has excellent imaging characteristics. The mean effective dose was 2.17E−02 ± 4.61E−03 mSv/MBq. It images constitutive tumour cell death and correlates with tumour cell death on histology.

Conclusion $^{68}$Ga-Ga-CDI is a novel cell death imaging radiopharmaceutical that is safe, has low radiation dosimetry and excellent biodistribution and imaging characteristics. It has potential advantages over previously investigated radiopharmaceuticals for imaging of cell death and has progressed to a proof-of-concept trial.

Trial registration ACTRN12621000641897 (28/5/2021, retrospectively registered)

Keywords Cell death · Apoptosis · Necrosis · Positron emission tomography · Positron emission tomography computed tomography · Gallium-68

Abbreviations

CDI Cell death indicator
CT X-ray computed tomography
DICOM Digital imaging and communications in medicine
DOTA 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid
DTPA Diethylene triamine pentaacetic acid
ECG Electrocardiograph
FDG 2-Fluoro-2-deoxyglucose
GSAO 4-(N-(S-glutathionylacetyl)amino)phenylarsenic acid
HPLC High performance liquid chromatography
hs90 Heat shock 90 proteins
LC-MS Liquid chromatography – mass spectroscopy
MRI Magnetic resonance imaging
NODAGA 2-(4,7-bis(carboxymethyl)-1,4,7-triazanon-1-yl)pentanedioic acid
PET Positron emission tomography
RECIST Response evaluation criteria in solid tumours

This article is part of the Topical Collection on Translational research

Ivan Ho Shon
i.hoshon@unsw.edu.au

1 Department of Nuclear Medicine and PET, Prince of Wales Hospital, Sydney, Australia
2 The Centenary Institute, University of Sydney, Sydney, Australia
3 Prince of Wales Clinical School, University of New South Wales, Sydney, Australia
4 School of Medical Sciences, University of Sydney, Sydney, Australia
**Introduction**

Assessment of response in oncology ultimately aims to measure tumour cell death following treatment. Cell death may be directly assessed in vitro and ex vivo by light microscopy, histochemical (e.g. annexin V staining, terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL)) and immunohistochemical (e.g. anti-caspase 3 antibodies) techniques. However, these require invasive and potentially morbid sampling procedures which may be difficult to perform repeatedly for serial dynamic assessment and such samples are small and may not be representative. Presently, imaging response assessment in oncology relies on indirect measurements of tumour cell death, most often assessing changes in tumour size using x-ray computed tomography (CT) assessed by Response Evaluation Criteria in Solid Tumours (RECIST) [1] or changes in metabolic activity using positron emission tomography (PET) with 2-fluoro-2-deoxyglucose (FDG) [2]. These modalities are imperfect for labelling GSAO with 68Ga to enable short interval serial measurements of tumour cell death, most often assessing changes in tumour size using x-ray computed tomography (CT) assessed by Response Evaluation Criteria in Solid Tumours (RECIST) [1] or changes in metabolic activity using positron emission tomography (PET) with 2-fluoro-2-deoxyglucose (FDG) [2]. These modalities are imperfect surrogates for tumour cell death.

Imaging of tumour cell death has the potential to overcome all the limitations of current clinical imaging for assessment of treatment efficacy. However, despite active investigation for over 20 years, it remains an unrealised opportunity. The most extensively investigated approach utilised the targeting of phosphatidylserine, which is externalised during apoptosis, with radiolabelled annexin V. Annexin V labelled with 99mTc was demonstrated to bind to and image apoptotic tumour cells [3] and increased tumour uptake of 99mTc-labelled annexin V has been observed in response to chemotherapy [4] and radiotherapy [5]. However 99mTc-labelled annexin V has high levels of physiologic uptake particularly in the kidneys and liver [6] and has not progressed into clinical practice [7]. Radiolabelled isatin-based inhibitors of activated caspase 3/7 have also been investigated for imaging of cell death. One of these, 18F-F-ICMT-11, underwent a first-in-human study which demonstrated high levels of hepatobiliary excretion that makes imaging of the abdomen and pelvis sub-optimal [8]. A proof-of-concept study was unsuccessful in imaging an increase in tumour cell death in response to chemotherapy in patients with breast and lung cancer [9].

4-(N-(5-glutathionylacetyl)amino)phenylarsonous acid (GSAO) is a tripeptide trivalent arsenical that when conjugated at the γ-glutamyl residue with fluorescent or radionuclide reporter probes is unable to enter viable cells. However, GSAO conjugates enter dying cells via organic anion transporters whether death is via apoptotic or non-apoptotic pathways [10]. Once in the cytosol, the As(III) atom of GSAO cross-links cysteines 597 and 598 of heat shock 90 proteins (hsp90) forming a covalent complex that prevents washout of the label from the cell [10]. Hsp90 is a highly abundant and stable target in dying/dead cells. GSAO conjugate labelling of dying/dead cells is rapid, specific and saturable, with intensity of labelling of dying/dead cells at least 1000-fold higher than that of viable cells [10]. In a murine colorectal carcinoma model following treatment with doxorubicin, tumour cells that stained with GSAO-fluorophore conjugates also stained for activated caspase 3 [10]. In an orthotopic murine mammary carcinoma model, GSAO fluorophore conjugates detected cyclophosphamide-induced tumour cell death that correlated with TUNEL-positive cells in sectioned tumours [11].

Initial in vivo studies of radionuclide conjugates of GSAO demonstrated that 111In conjugated to GSAO with diethylene triamine pentaacetic acid (DTPA) non-invasively imaged tumour cell death concordant with 99mTc-labelled annexin V with relatively lower levels of uptake in normal tissues and organs except for the kidneys [10]. GSAO was conjugated with 67Ga using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and this demonstrated higher tumour uptake and lower uptake in normal tissues and organs compared to 111In-DTPA GSAO [12]. Subsequently, a robust, convenient and broadly applicable method for labelling GSAO with 68Ga to enable short interval serial PET imaging was developed using the bifunctional chelator 2-(4,7-bis(carboxymethyl)-1,4,7-triazonan-1-yl)pentanedioic acid (NODAGA) [13], hereafter referred to as 68Ga Ga-Cell Death Indicator ([68Ga]Ga-CDI). In vivo studies demonstrated favourable biodistribution and imaging characteristics and predicted dosimetry similar to clinical 68Ga radiopharmaceuticals suitable for human use [14]. This study aimed to assess the first-in-human biodistribution, radiation dosimetry, safety and tumour uptake of [68Ga] Ga-CDI.

**Material and methods**

**Participants**

This open label, single arm interventional study recruited participants with histologically or cytologically confirmed solid malignancy with at least one measurable lesion > 2 cm. The study was approved by the South Eastern Sydney Local Health District Human Research Ethics committee (2019/ETH04821) and all participants signed an informed consent form. The study is registered with the Australian New Zealand Clinical Trials Registry (ACTRN12621000641897) and is...
registered with the Therapeutics Goods Administration of the Department of Health, Australian Government under the Clinical Trials Notification scheme (CT-2018-CTN-00827–1). Within 28 days of undergoing the study, participants were screened to ensure they met inclusion and exclusion criteria and written consent obtained. The full inclusion and exclusion criteria are shown in Table 1. Although not an inclusion criteria for participation in this study, all patients also underwent an FDG PET CT between 3 and 11 days prior to CDI PET CT as part of standard of care.

**[68Ga]Ga-CDI PET CT protocol and monitoring**

[68Ga]Ga-CDI was prepared as previously described. In summary, CDI was first prepared by dissolving GSAO in 0.1 N sodium bicarbonate. 2,2-

summary, CDI was first prepared by dissolving GSAO in

2-(7-(1-carboxy-4-((2,5-diox-

opyrrolidin-1-yl)oxy)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)

diacetic acid (NODAGA-NHS, Chematech) was dissolved in anhydrous dimethylformamide and added to the reaction mixture dropwise over 1 h. The reaction mixture was stirred for 4 h, acidified by the addition of 1 N hydrochloric acid, shock-frozen in liquid nitrogen and freeze-dried. The residue was redissolved in de-aerated water and purified by high performance liquid chromatography (HPLC). Purity was confirmed by liquid chromatography–mass spectroscopy (LC–MS) and frozen in 100 µL aliquots (54 µg).

CDI was radiolabelled by eluting [68 Ga]Cl3 from the Ge/Ga generator (Eckert and Ziegler-IGG-100) onto a cation exchange cartridge (Agilent Bond Elut SCX). 68 Ga (III) was then eluted from the cation exchange cartridge using a mixture of hydrochloric acid (HCl) and sodium chloride (NaCl) (12.5 µL of 5.5 N HCl and 500 µL of 5 N NaCl) into a reaction vial containing 54 µg of CDI, ascorbic acid (4.4 mg in 100 µl), sodium acetate buffer (250 µL, 1.5 N, pH 4.5) and 3.5 mL water (Ultrapur). The reaction vial was incubated at room temperature for 10 min. Phosphate buffer (3 mL, 384 mM, pH 7.9) was added and the mixture filtered through a 0.22-µm filter (Millipore Millex-GV 33 mm). Quality control was performed with HPLC and thin layer chromatography (TLC) [13].

Participants were encouraged to be well orally hydrated prior to [68Ga]Ga-CDI administration; otherwise, there was no preparation required. Two intravenous cannulas were placed (one for administration of [68Ga]Ga-CDI and the other for blood sampling during the study). Immediately prior to [68Ga]Ga-CDI administration, clinical assessment of participants was performed, vital signs (blood pressure, heart rate, respiratory rate, arterial oxygen saturation and temperature) measured and a 12-lead electrocardiogram (ECG) obtained and QTc calculated according to Bazett’s formula to confirm eligibility. [68Ga]Ga-CDI was administered as an intravenous bolus. The mean and standard deviation of the administered mass of [68Ga]Ga-CDI was 40.1 ± 5.8 µg (range, 32.8–48.8 µg). The mean and standard deviation of administered activity was 205 ± 4.1 MBq (range 200–211 MBq) of [68Ga]Ga-CDI.

Eight serial PET scans were then performed from skull vertex to the proximal femora. The first PET scan commenced immediately following administration of [68Ga] Ga-CDI, with subsequent scans commencing at approximately 7, 17, 29, 47, 64, 120 and 180 min after administration (+/- 5 min). All scans were performed on a Phillips ingenity TF 128 PET CT scanner (Philips Medical Systems, Cleveland) with acquisition times increasing for each subsequent scan ranging from 30 (immediately after administration) to 240 s/bed (at 180 min after administration) to compensate for excretion and decay. All PET scans were reconstructed using CT attenuation correction with a time of flight, list-mode, blob-based, ordered subsets maximum likelihood expectation maximisation algorithm (BLOB-OS-TF) (3 iterations, 3 subsets, kernel width = 18.1 cm, relaxation parameter = 1, reconstructed voxel size 4 x 4 x 4 mm).

| Table 1 | Inclusion and exclusion criteria |
|-----------------|-----------------------------------|
| **Inclusion criteria** | **Exclusion criteria** |
| Able to understand and willing to sign the written informed consent | Cancer treatment within the previous 6 weeks |
| Male or female patients ≥ 18 years of age | Primary or isolated metastatic CNS malignancy |
| Histologically or cytologically confirmed solid malignancy with at least one measurable lesion > 2 cm | Active uncontrolled infection |
| Within 28 days of commencement: Adequate liver function (bilirubin ≤ 1.5 upper limit normal (ULN), ALT and AST ≤ 4 ULN) | Congestive heart failure or prior NYHA class III–IV cardiac disease |
| Adequate renal function (eGFR > 50 mL/min/1.73 m²) | Uncontrolled hypertension (systolic BP > 180 mmHg or diastolic BP > 100 mmHg) |
| Adequate bone marrow function (absolute neutrophil count ≥ 1.5 x 10⁹/L, haemoglobin level ≥ 9.0 g/dL and platelets ≥ 100 x 10⁹/L) | Evidence of recent heart disease (myocardial infarction in the past 3 months by ECG, arrhythmias associated with QTc prolongation or evidence of ischemia) |
| Serum potassium ≥ 3.0 mmol/L and magnesium ≥ 0.6 mmol/L | QTc > 480 ms |
| | Medications that prolong QTc |
| | Pregnancy |
| | Breast feeding |
Immediately prior to the sixth PET scan commencing at approximately 47 min post administration, a low-dose, non-contrast CT of the same region was performed for attenuation correction and localisation (of the first six scans during which time the patient had not moved) (44–120 mAs, 120–140 kV adjusted for body weight and body mass index, iDose 3 iterative reconstruction, reconstructed voxel size 1.17 × 1.17 × 3 mm). Ultra-low dose non-contrast CT (25 mAs, 100 kV, filtered back projection reconstruction, reconstructed voxel size 1.17 × 1.17 × 3 mm) was performed for attenuation correction immediately prior to the 120-min and 180-min PET scans (previous work validated the quantitative accuracy of these ultra-low-dose CT for attenuation correction) [15].

During and immediately following completion of the scanning protocol, participants were clinically assessed for adverse reactions and vital signs measured. Blood was collected for venous radioactivity measurements at 1, 2 and 3 h following [68Ga]Ga-CDI administration. Participants were asked to void between 1.5 to 2 h and 2.75 to 3 h after [68Ga] Ga-CDI administration, urine collected, the volume measured and an aliquot counted in a cross calibrated gamma counter to determine activity concentration. Following completion of the scanning protocol, ECG was recorded, and blood was collected for biochemical and haematological assessment.

Post [68Ga]Ga-CDI PET CT monitoring

On the day following the [68Ga]Ga-CDI PET CT, participants were clinically assessed for adverse reactions and vital signs, ECG was obtained, and blood was collected for biochemical and haematological assessment. Clinical follow-up was also performed 7 days later for assessment of adverse reactions.

Analysis of [68Ga]Ga-CDI PET CT scans

For analysis of uptake and biodistribution in normal tissues and organs, spherical volumes of interest (VOIs) were drawn on the Digital Imaging and Communications in Medicine (DICOM) [68Ga]Ga-CDI-PET emission data on a workstation (IntelliSpace Portal, V5.0.2.60000, Philips Medical System, Best, The Netherlands) by an experienced nuclear medicine physician over clearly tumour-free regions of organs and the left ventricular and aortic blood pool (the average of which was used for blood pool activity). The imaging-derived blood pool activity was used for biodistribution and dosimetry calculations (the blood pool activity measured from the venous blood samples collected correlated closely with the imaging-derived blood pool activity but was not used for calculation of biodistribution and dosimetry). VOI diameter varied depending on organ size but where possible was at least 10 mm. Spherical VOIs were also drawn over all tumour deposits greater than 10 mm in diameter. These VOIs were replicated across all time points and the mean, maximum and standard deviation of the activity concentration (Bq/mL) of all VOIs at each time point was recorded. Activity concentration was used to calculate the % injected activity (%IA) for organs and tissues based on the masses of source organs for standard phantom male and female models [16]. Mean, maximum and standard deviation of the SUV for each VOI was also calculated from the activity concentration using the slope intercept stored with the DICOM CDI PET emission data.

Radiation dosimetry

Activity concentrations derived above were entered into OLINDA/EXM 1.1 and bi-exponential curves fitted using the curve fitting tools within OLINDA/EXM 1.1 [17]. A urinary bladder filling and voiding model were derived. Organ and total body effective dose was calculated using ICRP publication 103 weighting factors [18].

Histological correlation

In one participant, who proceeded to surgical excision of the tumour deposits 1 day after the [68Ga]Ga-CDI PET study, histological correlation of the tumour deposits was undertaken using haematoxylin and eosin staining and TUNEL staining to specifically identify dead and dying cells. Representative samples of the formalin fixed surgical specimens (following completion of all clinical analysis and excess to that required for archival purposes) from the right axillary and right cervical nodal masses were selected and provided by the reporting clinical pathologist. The tissues were fixed, rehydrated with ethanol and xylene and embedded in paraffin. A series of 4 µm thick sections were cut and stained with haematoxylin and eosin. Apoptotic cells were stained using the TUNEL assay kit HRP-DAB (Abcam, Cat#206,386, Cambridge, MA, USA) according to manufacturer’s protocol. Briefly, 4-µm sections of paraffin embedded tumour were deparaffinised in xylene and rehydrated in decreasing concentrations of ethanol. Tumour sections were permeabilized with Proteinase K for 20 min at room temperature. The endogenous peroxidase activity was quenched with 3% H2O2 for 5 min. Apoptotic cells were labelled with biotinylated Terminal deoxynucleotidyl Transferase (TdT) at 37 °C in a humidified chamber for 2 h followed by a 30-min incubation with streptavidin-HRP conjugate. HRP-positive cells were developed using diaminobenzidine (DAB) and specimens were counterstained with methyl green (Sigma, St Louis, MO, USA). The entire tumour section was imaged using PowerMosaic scanning at 10× magnification on a Leica DM6000D microscope.
Results

Participants

Five participants were recruited to this study, three females and two males, ranging in age from 52 to 81 years (Table 2).

Safety and tolerability

$[^{68}\text{Ga}]$Ga-CDI was well-tolerated. There were no adverse or clinically detectable pharmacologic effects in any of the 5 participants. No significant changes in vital signs or the results of laboratory studies or electrocardiograms were observed.

Biodistribution and imaging

Following $[^{68}\text{Ga}]$Ga-CDI administration, there is rapid distribution in the blood pool, with rapid renal uptake and excretion. Of the organs and tissues, the greatest amount of activity is within the blood pool with on average 12.2%, 8.8% and 7.7% IA remaining in the blood pool at 1, 2 and 3 h, respectively. The highest concentration of activity is within the kidneys with an average SUV of 5.3, 4.9 and 4.0 at 1, 2 and 3 h post injection, respectively (Fig. 1). The remaining organs demonstrated lower activity concentrations and there was a progressive decline in activity in all organs over time. By 90 min, 39 ± 18% of total activity has been excreted in urine.

Serial PET imaging demonstrates rapid distribution in the blood pool, renal uptake and excretion with low levels of physiologic uptake in the remaining organs. Representative images of one participant are shown in Fig. 2 (images of the remaining participants are in Supplemental Data).

Tumour uptake

Tumour uptake is variable depending on tumour histology. High uptake is seen in squamous cell carcinoma of the oesophagus (SUVmax 5.7) and metastatic cutaneous squamous cell carcinoma (SUVmax 6.5), moderate uptake in

Table 2  Participant characteristics

| Participant | Age | Gender | Diagnosis                                                                 | Site(s) of disease                                      | Previous treatment(s)        | Interval since last treatment |
|-------------|-----|--------|----------------------------------------------------------------------------|-------------------------------------------------------|-----------------------------|------------------------------|
| 1           | 66  | M      | Squamous cell carcinoma of oesophagus                                     | Upper oesophagus                                       | New diagnosis               | Not applicable               |
| 2           | 73  | F      | High grade serous carcinoma of the ovary                                  | Peritoneum                                             | Surgery, chemotherapy       | 12 weeks                     |
| 3           | 66  | F      | Squamous cell carcinoma (cutaneous)                                       | Lymph nodes (right upper anterior cervical triangle and right axilla) | New diagnosis               | Not applicable               |
| 4           | 81  | F      | Grade II invasive ductal breast carcinoma, oestrogen receptor–positive, HER-2-negative | Right breast and right axillary lymph node             | New diagnosis               | Not applicable               |
| 5           | 52  | M      | Adenocarcinoma (colon)                                                   | Liver and retroperitoneal lymph nodes                  | Multiple surgeries, chemotherapy | 11 months                   |

Fig. 1  Mean %IA (A) and SUV (B) for selected tissues/organs
metastatic colorectal carcinoma (SUVmax 4.4) and lower uptake in metastatic ovarian carcinoma (SUVmax 2.7) and breast carcinoma (SUVmax 2.5). In contrast to normal tissues and organs, tumour in 4 of the 5 patients demonstrated prolonged retention throughout the duration of imaging, with a commensurate increase in tumour to blood pool activity progressively declined (Fig. 3).

**Radiation dosimetry**

The average effective dose is $2.17E-02 \pm 4.61E-03$ mSv/MBq. Average organ doses are shown in Table 3. In all cases, the dose limiting organ was the urinary bladder wall $(2.79E-01 \pm 1.11E-01$ mSv/MBq) followed by the kidneys $(4.89E-02 \pm 3.55E-03$ mSv/MBq). Individual participant dosimetry is in the Supplemental Data.

**Histological correlation**

Participant 3 presented with a nodal mass in the right axilla; biopsy of which demonstrated squamous cell carcinoma, thought to be metastatic from a previously excised cutaneous primary. During pre-operative assessment prior to resection of the right axillary nodal metastatic disease, CT and FDG PET CT demonstrated further nodal metastatic disease in the right upper neck. Given the anatomical location and clinical history (the participant previously had multiple cutaneous squamous cell carcinomas resected from the head, neck and trunk), the treating surgeon considered that this was likely to represent metastatic disease from a different cutaneous primary to that responsible for the right axillary nodal metastatic disease. The patient proceeded to right lateral neck dissection and right axillary dissection 1 day after the $[^{68}\text{Ga}]$Ga-CDI PET study. Representative sections of the right axillary nodal metastases demonstrated many more TUNEL-positive cells than the right cervical nodal metastases. Corresponding haematoxylin and eosin–stained sections demonstrated that the TUNEL-positive cells corresponded to squamous cell carcinoma and adjacent normal lymphoid tissue did not demonstrate TUNEL staining. The number of TUNEL-positive cells correlated with the intensity of $[^{68}\text{Ga}]$Ga-CDI uptake (Fig. 4).

**Discussion**

This first-in-human study reports on a novel radiopharmaceutical, $[^{68}\text{Ga}]$Ga-CDI, for imaging of cell death that is safe, well-tolerated, has dosimetry similar to clinical $[^{68}\text{Ga}]$Ga radiopharmaceuticals and demonstrates excellent biodistribution and imaging characteristics. $[^{68}\text{Ga}]$Ga-CDI overcomes most of the limitations encountered with previous attempts at molecular imaging of cell death and creates opportunities for personalised treatment based on near real-time imaging of treatment-induced cell death in cancer.

The safety, tolerability and absence of side effects and adverse events from $[^{68}\text{Ga}]$Ga-CDI were an expected observation. Although $[^{58}\text{Ga}]$Ga-CDI contains an arsenic atom, the active phenylarsenous targeting moiety of CDI, GSAO, has been previously assessed in a phase I study in patients with advanced solid tumours as a mitochondrial toxin. GSAO was infused 5 days per week for 2 weeks in every three and found to have a maximum tolerated dose of 22 mg/m²/day, which is almost 1000-fold greater than the administered mass in this study [19].

This study utilised dosimetry methodology employed for other $[^{68}\text{Ga}]$Ga radiopharmaceuticals currently in clinical practice. Walker et al. reported the dosimetry of $[^{68}\text{Ga}]$Ga-CDI overcomes most of the limitations encountered with previous attempts at molecular imaging of cell death and creates opportunities for personalised treatment based on near real-time imaging of treatment-induced cell death in cancer.

The safety, tolerability and absence of side effects and adverse events from $[^{68}\text{Ga}]$Ga-CDI were an expected observation. Although $[^{58}\text{Ga}]$Ga-CDI contains an arsenic atom, the active phenylarsenous targeting moiety of CDI, GSAO, has been previously assessed in a phase I study in patients with advanced solid tumours as a mitochondrial toxin. GSAO was infused 5 days per week for 2 weeks in every three and found to have a maximum tolerated dose of 22 mg/m²/day, which is almost 1000-fold greater than the administered mass in this study [19].

This study utilised dosimetry methodology employed for other $[^{68}\text{Ga}]$Ga radiopharmaceuticals currently in clinical practice. Walker et al. reported the dosimetry of $[^{68}\text{Ga}]$Ga-CDI overcomes most of the limitations encountered with previous attempts at molecular imaging of cell death and creates opportunities for personalised treatment based on near real-time imaging of treatment-induced cell death in cancer.

The safety, tolerability and absence of side effects and adverse events from $[^{68}\text{Ga}]$Ga-CDI were an expected observation. Although $[^{58}\text{Ga}]$Ga-CDI contains an arsenic atom, the active phenylarsenous targeting moiety of CDI, GSAO, has been previously assessed in a phase I study in patients with advanced solid tumours as a mitochondrial toxin. GSAO was infused 5 days per week for 2 weeks in every three and found to have a maximum tolerated dose of 22 mg/m²/day, which is almost 1000-fold greater than the administered mass in this study [19].

This study utilised dosimetry methodology employed for other $[^{68}\text{Ga}]$Ga radiopharmaceuticals currently in clinical practice. Walker et al. reported the dosimetry of $[^{68}\text{Ga}]$Ga-CDI overcomes most of the limitations encountered with previous attempts at molecular imaging of cell death and creates opportunities for personalised treatment based on near real-time imaging of treatment-induced cell death in cancer.
Ga-dotatate in 6 participants and found that the mean effective dose was $2.57 \times 10^{-2} \text{ mSv/MBq}$ and renal dose was $9.21 \times 10^{-2} \text{ mSv/MBq}$ [20]. A study comprising 4 participants found $[^{68}\text{Ga}]$Ga-PSMA had a mean effective dose of $2.3 \times 10^{-2} \text{ mSv/MBq}$, renal dose of $2.6 \times 10^{-1} \text{ mSv/MBq}$ and a urinary bladder dose of $1.3 \times 10^{-1} \text{ mSv/MBq}$ [21]. Another study of $[^{68}\text{Ga}]$Ga-PSMA dosimetry which included 5 participants reported an effective dose of $2.37 \times 10^{-2} \text{ mSv/MBq}$, renal dose of $1.21 \times 10^{-1} \text{ mSv/MBq}$ and urinary bladder dose of $1.64 \times 10^{-1} \text{ mSv/MBq}$ [22]. In summary, compared to both $[^{68}\text{Ga}]$Ga-dotatate and $[^{68}\text{Ga}]$-PSMA, $[^{68}\text{Ga}]$Ga-CDI has a slightly lower effective dose and renal dose but a slightly higher urinary bladder dose and is therefore well-suited for routine and repeated human use.

Aside from the renal tract, which is the route of excretion, physiologic uptake of $[^{68}\text{Ga}]$Ga-CDI is low. In comparison, the activated caspase 3/7 agent, $[^{18}\text{F}]$ICMT, has high levels of uptake in the hepatobiliary system and bowel as it undergoes both hepatobiliary and renal excretion [8]. Similarly, many annexin V radiopharmaceuticals demonstrate very high physiologic uptake in the kidneys (49.7% IA) and liver (13.1% IA) and prolonged retention [6]. The biodistribution characteristics of $[^{68}\text{Ga}]$Ga-CDI translate to ideal imaging characteristics with minimal or no interference from physiologic uptake, whereas high physiologic uptake observed with other cell death imaging radiopharmaceuticals especially in the hepatobiliary system and bowel makes abdominal and pelvic imaging suboptimal. Furthermore, as CDI is labelled with $^{68}$Ga, it enables short-interval serial PET for near real time, quantitative dynamic assessment of treatment-induced changes in tumour cell death.

Whilst acceptable dosimetry, good biodistribution and imaging characteristics are important, for a cell death imaging agent to be successful, it must have the sensitivity to quantitively detect tumour cell death. In vitro assessments of fluorophore conjugates of GSAO demonstrated rapid and specific uptake in dying/dead tumour cells. Half-maximal uptake in cultured tumour cells occurred in ~2 min and the specificity for dying/dead versus viable cells was at least 1000-fold [10]. In this study, $[^{68}\text{Ga}]$Ga-CDI detected constitutive tumour cell death with levels of $[^{68}\text{Ga}]$Ga-CDI uptake varying between different tumour types but also within tumours of the same histological subtype. The variations in intensity of uptake in different tumours is likely due
to varying rates of constitutive tumour cell death. Tumour constitutive necrosis correlates with tumour aggressiveness [23]. Participants 2 and 5 both had metastatic disease which remained relatively stable for many months without active treatment, suggesting relatively indolent behaviour and hence likely low rates of constitutive tumour necrosis underlying the low level of $[^{68}\text{Ga}]\text{Ga-CDI}$ uptake in their tumour deposits. In addition, $[^{68}\text{Ga}]\text{Ga-CDI}$ tumour uptake correlated with histological tumour cell death assessed by TUNEL on operative specimens. Tumour uptake generally peaks at approximately 60 min post injection and remains stable thereafter. However, tumour:blood pool ratios continue to rise beyond this due to progressive clearance of activity from the blood pool. Taken together and considering the half-life of $^{68}\text{Ga}$, it is likely that the optimal imaging time is between 1 and 2 h after injection.

The ability to detect constitutive tumour cell death demonstrates the sensitivity of $[^{68}\text{Ga}]\text{Ga-CDI}$ for imaging tumour cell death. In contrast, previous radiopharmaceuticals for imaging cell death did not reliably detect tumour cell death even after treatment. For example, the caspase ligand $[^{18}\text{F}]\text{ICMT}$ did not detect an increase in cell death in a proof-of-concept study. This was attributed to the low abundance and spatial and temporal heterogeneity of the target and that response may occur by mechanisms independent of caspase 3/7 activation [9]. Gammon et al. suggested that a long integration would be required to overcome these limitations [24]. $[^{68}\text{Ga}]\text{Ga-CDI}$ resolves these limitations. Firstly, hsp90 is highly abundant, constituting up to 1–2% of total cellular protein content and is often upregulated in malignancy [25], providing many potential binding sites in each dead and dying tumour cell. This makes hsp90 an ideal target for imaging cell death and it is likely that the high abundance of hsp90 underlies the ability of $[^{68}\text{Ga}]\text{Ga-CDI}$ to image even small numbers of dead and dying tumour cells such as occurs with constitutive tumour cell death. Furthermore, even in tumours with low rate of constitutive cell death (and hence low $[^{68}\text{Ga}]\text{Ga-CDI}$ uptake prior to treatment), $[^{68}\text{Ga}]\text{Ga-CDI}$ is still likely to be able to detect treatment response as even a small increase in tumour cell death following treatment should be detectable with $[^{68}\text{Ga}]\text{Ga-CDI}$ PET. Secondly, it is a spatially and temporally stable target, as once a cell is committed to death, the target is accessible and stable until the cellular debris is cleared by physiologic mechanisms, which may take several weeks. The optimal time for imaging tumour cell death with $[^{68}\text{Ga}]\text{Ga-CDI}$ after commencing treatment remains to be determined. Until now, effective methods for imaging tumour cell death in vivo have not been available to image the kinetics of tumour cell death following therapy and it is possible that this may vary between different treatment classes and modalities. Additional preclinical and clinical kinetic studies are warranted to further characterise this. However, the combination of preclinical studies with fluorophore-labelled GSAO demonstrating an increase in treatment induced tumour cell death 1 day following a single dose of chemotherapy, and the likely slow clearance of dead and dying cells from the tumour bed suggests that optimal imaging is likely to be within days to a few weeks after commencing treatment. Finally, in contrast to previous cell death imaging radiopharmaceuticals which have largely targeted aspects of apoptosis, $[^{68}\text{Ga}]\text{Ga-CDI}$ detects different forms of cell death and there is increasing evidence of the importance of non-apoptotic cell death in malignancy [26].

The development of optimal and widely accessible molecular imaging of tumour cell death creates many new opportunities to improve outcomes in oncology. Most obviously, cell death imaging has the potential to assess treatment response more accurately and rapidly. Although current imaging modalities such as CT, FDG PET and MRI have proven utility for assessing treatment response, in many circumstances they are suboptimal. For example, following radiotherapy treatment, related effects such as fibrosis

### Table 3 Average radiation dose for individual organs (SD standard deviation, %COV percentage coefficient of variation, LLI lower large intestine, ULI upper large intestine)

| Target organ             | Estimated radiation dose (mSv/MBq) | Average | SD   | %COV |
|--------------------------|------------------------------------|---------|------|------|
| Adrenals                 | 1.28E-02                           | 4.21E-03| 3.28E+01|
| Brain                    | 1.75E-03                           | 2.96E-04| 1.69E+01|
| Breasts                  | 7.03E-03                           | 3.52E-03| 5.01E+01|
| Gallbladder wall         | 8.16E-03                           | 1.42E-03| 1.74E+01|
| LLI wall                 | 1.91E-02                           | 5.87E-03| 3.07E+01|
| Small intestine          | 1.45E-02                           | 3.59E-03| 2.47E+01|
| Stomach wall             | 1.00E-02                           | 3.76E-03| 3.76E+01|
| ULI wall                 | 1.23E-02                           | 4.88E-03| 3.96E+01|
| Heart wall               | 1.02E-02                           | 1.95E-03| 1.90E+01|
| Kidneys                  | 4.89E-02                           | 3.55E-03| 7.26E+00|
| Liver                    | 1.61E-02                           | 3.54E-03| 2.19E+01|
| Lungs                    | 7.75E-03                           | 1.07E-03| 1.38E+01|
| Muscle                   | 8.96E-03                           | 2.17E-03| 2.42E+01|
| Ovaries                  | 1.20E-02                           | 3.00E-03| 2.51E+01|
| Pancreas                 | 1.52E-02                           | 5.12E-03| 3.38E+01|
| Red marrow               | 8.89E-03                           | 1.33E-03| 1.50E+01|
| Osteogenic cells         | 1.13E-02                           | 3.03E-03| 2.69E+01|
| Skin                     | 5.39E-03                           | 1.41E-03| 2.61E+01|
| Spleen                   | 1.59E-02                           | 3.63E-03| 2.28E+01|
| Testes                   | 1.67E-02                           | 3.26E-03| 1.95E+01|
| Thymus                   | 6.32E-03                           | 1.65E-03| 2.60E+01|
| Thyroid                  | 1.26E-02                           | 3.89E-03| 3.08E+01|
| Urinary bladder wall     | 2.79E-01                           | 1.11E-01| 3.97E+01|
| Uterus                   | 2.63E-02                           | 1.17E-03| 4.43E+00|
| Total Body               | 9.66E-03                           | 1.57E-03| 1.63E+01|
| Effective dose           | 2.17E-02                           | 4.61E-03| 2.13E+01|

© Springer
and post radiotherapy inflammatory change make anatomic and molecular imaging inaccurate [27]. Accurate imaging assessment of treatment response in immuno-oncology is another major unmet need. In such circumstances, imaging assessment of treatment response may be inaccurate and often delayed until treatment-induced effects have subsided. Imaging of changes in tumour cell death following treatment provides the opportunity for much earlier and more accurate assessment of treatment response in such situations.

Imaging-guided response–adapted individualised treatment provides the opportunity to improve outcomes in oncology but is predicated by imaging that provides timely and sufficiently accurate response assessment. With the possible exception of FDG PET in Hodgkin’s and non-Hodgkin’s lymphoma, current imaging modalities are inadequate. For example, in breast carcinoma being treated with neoadjuvant systemic therapy, MRI and FDG PET are moderately accurate for prediction of pathological response; however, neither are sufficiently accurate to avoid unnecessary surgery in patients who have a complete pathological response following neoadjuvant therapy [28]. Similar challenges exist in oesophageal and rectal carcinoma with neoadjuvant therapy [29]. Even when imaging is combined with clinical and histological assessment, it remains inadequate to determine if patients should proceed to surgery or may be safely managed with a “watch and wait” approach. Beyond clinical care, cell death imaging provides significant opportunities to improve the conduct of clinical trials by imaging a specific and direct biomarker to identify active agents or combinations. Furthermore, cell death imaging of healthy organs and tissues will provide direct assessment of toxicity and may enable rational customised dose escalation strategies.

Conclusions

[68Ga]Ga-CDI is a novel radiopharmaceutical for imaging of cell death. It is safe, has radiation dosimetry similar to clinical 68Ga radiopharmaceuticals and demonstrates optimal biodistribution and imaging characteristics. It is able to detect constitutive tumour cell death and uptake correlates with histological cell death. It is now entering a proof-of-concept trial and has the potential to improve treatment...
response assessment and enable cell death imaging–adapted personalised treatment approaches.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00259-022-05880-z.

Acknowledgements Dr Melvin Chin (Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia and Faculty of Medicine, University of New South Wales, Sydney, Australia). Dr Walter Haindl (Department of Nuclear Medicine and PET, Prince of Wales Hospital, Sydney, Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia). Prof David Goldstein (Department of Medical Oncology, Prince of Wales Hospital, Sydney, Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia). A/Prof Michael Jackson (Department of Radiation Oncology, Prince of Wales Hospital, Sydney, Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia). A/Prof Iain Heuvel (Department of Radiation Oncology, Prince of Wales Hospital, Sydney, Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia). Dr C. Lehane (Department of Surgery, Prince of Wales Hospital, Sydney, Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia). Dr Stephen Thompson (Department of Radiation Oncology, Prince of Wales Hospital, Sydney, Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia). Dr Charlotte Lemech (Medical Director, Scientia Clinical Research, Sydney, Australia). Dr Rowena Martin (Department of Radiation Oncology, Prince of Wales Hospital, Sydney, Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia). A/Prof Monica A Rossleigh (Department of Nuclear Medicine and PET, Prince of Wales Hospital, Sydney, Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia). Brent Rogers (Radiation and Laser Safety Officer, Prince of Wales, Sydney/ Sydney Eye, Royal Women’s and Sydney Children’s Hospitals). Megan Horsfield (Department of Nuclear Medicine and PET, Prince of Wales Hospital, Sydney, Australia). Dr Katrina Tang (Anatomical Pathology, Prince of Wales Hospital, Sydney, Australia). Dr Stephen Thompson (Department of Radiation Oncology, Prince of Wales Hospital, Sydney, Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia). Dr Eva Wegner (Department of Nuclear Medicine and PET, Prince of Wales Hospital, Sydney, Australia and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia). The participants in this study.

Author contribution IH co-designed the study, performed production of [68 Ga]Ga-CDI, assisted with patient safety monitoring, performed most of data analysis and wrote the manuscript. TH and BM undertook radiation dosimetry calculations and oversaw radiation safety. JG oversaw production of [68 Ga]Ga-CDI and provided independent quality control and product release. MG produced CDI to Good Laboratory Practice standards and RC oversaw this production. AL undertook histological analysis of tumour specimens. PH co-designed the study and edited the manuscript.

Funding Open Access funding enabled and organized by CAUL and its Member Institutions. This work was supported by grants to PJH from the National Health and Medical Research Council of Australia (1002645, PG 11-03) and Australian Cancer Research Foundation of Australia (PCT/AU2020/050359). The other authors have no interests to declare.

Data availability Anonymised source data from this study is available with investigator support, after approval of a proposal and with a signed data access agreement.

Declarations

Ethics approval The study was performed in line with the principles of the Declaration of Helsinki and has been approved by the South Eastern Sydney Local Health District Human Research Ethics committee (2019/ETH04821).

Consent to participate All participants signed an informed consent prior to participation in this study. The authors affirm that human research participants provided informed consent for publication of the images in Figs. 2 and 4 and Figs. 1, 2, 3, and 4 of the Supplemental Data.

Conflict of interest PH and IH are listed as co-inventors on the patent PCT/AU2020/050359. The other authors have no interests to declare.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Schwartz LH, Bogaerts J, Ford R, Shankar L, Therasse P, Gwyther S, et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer. 2009;45:261–7. https://doi.org/10.1016/j.ejca.2008.10.028.

2. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50(Suppl 1):122S-8150. https://doi.org/10.2967/jnumed.108.057307.

3. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. Imaging of apoptosis (programmed cell death) with 99mTc-annexin V. J Nucl Med. 1999;40:184–91.

4. Bellhoci T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, et al. Increased uptake of the apoptosis imaging agent 99mTc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res. 2002;8:2766–74.

5. Haas RL, de Jong D, Valdes Olmos RA, Hefnagel CA, van den Heuvel I, Zerp SF, et al. In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. Int J Radiat Oncol Biol Phys. 2004;59:782–7. https://doi.org/10.1016/j.ijrobp.2003.11.017/S0360301603023125[pii].

6. Kemerink GJ, Liu X, Kieffer D, Ceysens S, Mortelmans L, Verbruggen AM, et al. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J Nucl Med. 2003;44:947–52.

7. Bellhoci T, Blankenberg FG, Kartachova MS, Stitt LW, Vanderheiden JL, Hoebers FJ, et al. (99m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. Eur J Nucl Med Mol Imaging. 2015;42:2083–97. https://doi.org/10.1007/s00259-015-3152-0.

8. Challapalli A, Kenny LM, Hallett WA, Kozlowski K, Tomasi G, Gudi M, et al. 59F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med. 2013;54:1551–6. https://doi.org/10.2967/jnumed.112.118760.

9. Dubash SR, Merchant S, Heinzmann K, Mauri F, Lavdas I, Inglese M, et al. Clinical translation of 59F-ICMT-11 for measuring chemotheraphy-induced caspase 3/7 activation in breast and lung cancer.
Eur J Nucl Med Mol Imaging. 2018;45:2285–99. https://doi.org/10.1007/s00259-018-4098-9.

10. Park D, Don AS, Massamiri T, Karwa A, Warner B, MacDonald J, et al. Noninvasive imaging of cell death using an Hsp90 ligand. J Am Chem Soc. 2011;133:2832–5. https://doi.org/10.1021/ja110226y.

11. Park D, Xie BW, Van Beek ER, Blankevoort V, Que I, Lowik CW, et al. Optical imaging of treatment-related tumor cell death using a heat shock protein-90 alkylator. Mol Pharm. 2013;10:3882–91. https://doi.org/10.1021/mp4003464.

12. Ho Shon I, Kumar D, Sathikumar C, Berghoffer P, Van K, Chicco A, et al. Biodistribution and imaging of an hsp90 ligand labelled with $^{111}$In and $^{68}$Ga for imaging of cell death. EJNMMI Res. 2020;10:4. https://doi.org/10.1186/s13550-020-0590-x.

13. Ho Shon I, Gotsbacher MP, Guille J, Kumar D, Codd R, Hogg P. Preparation of a dithiol-reactive probe for PET imaging of cell death. Methods Mol Biol. 2019;1967:295–304. https://doi.org/10.1007/978-1-4939-9187-7_19.

14. Ho Shon I, Kumar D, Schreuder M, Guille J, Doan J, Sathikumar C, et al. Preclinical assessment of $[^{68}\text{Ga}]$Ga-cell death indicator (CDI): a novel hsp90 ligand for positron emission tomography of cell death. Curr Radiopharm. 2021;14:1-. https://doi.org/10.2174/187447101466621112100646.

15. Ho Shon I, Reece C, Hennessy T, Horsfield M, McBride B. Influence of X-ray computed tomography (CT) exposure and reconstruction parameters on positron emission tomography (PET) quantitation. EJNMMI Phys. 2020;7:62. https://doi.org/10.1186/s40458-020-00331-w.

16. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85:294–310.

17. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.

18. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37:1–332. https://doi.org/10.1016/j.icrp.2007.10.003.

19. Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, et al. A phase 1 trial of intravenous 4-((N-((S-glutathionyl)cetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2013;72:1343–52. https://doi.org/10.1007/s00280-013-2320-9.

20. Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M. Measured human dosimetry of $^{68}$Ga-DOTATATE. J Nucl Med. 2013;54:855–60. https://doi.org/10.2967/jnumed.112.114165.

21. Afshar-Oromieh A, Hetzheim H, Kubler W, Kratochwil C, Giesel FL, Hope TA, et al. Radiation dosimetry of $^{68}$Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging. 2016;43:1611–20. https://doi.org/10.1007/s00259-016-3419-0.

22. Pfob CH, Ziegler S, Graner FP, Kohner M, Schachoff S, Blechert B, et al. Biodistribution and radiation dosimetry of $^{68}$Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:1962–70. https://doi.org/10.1007/s00259-016-3424-3.

23. Caruso R, Parisi A, Bonanno A, Paparo D, Quattrocchi E, Branca G, et al. Histologic coagulative tumour necrosis as a prognostic indicator of aggressiveness in renal, lung, thyroid and colorectal carcinomas: a brief review. Oncol Lett. 2012;3:16–8. https://doi.org/10.3892/ol.2011.420.

24. Gammon ST, Engel BJ, Gores GI, Cressman E, Piwnica-Worms D, Millward SW. Mistiming death: modeling the time-domain variability of tumor apoptosis and implications for molecular imaging of cell death. Mol Imaging Biol. 2020;22:1310–23. https://doi.org/10.1007/s11307-020-01509-5.

25. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer. 2005;5:761–72. https://doi.org/10.1038/mrc1716.

26. Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486–541. https://doi.org/10.1038/s41418-017-0012-4.

27. Wiegman EM, Pruim J, Ubbels JF, Groen HJ, Langendijk JA, Widder J. (18)F-FDG PET during stereotactic body radiotherapy for stage I lung tumours cannot predict outcome: a pilot study. Eur J Nucl Med Mol Imaging. 2011;38:1059–63. https://doi.org/10.1007/s00259-010-1706-8.

28. Tian F, Shen G, Deng Y, Diao W, Jia Z. The accuracy of (18)F-FDG PET/CT in predicting the pathological response to neoadjuvant chemotherapy in patients with breast cancer: a meta-analysis and systematic review. Eur Radiol. 2017;27:4786–96. https://doi.org/10.1007/s00330-017-4831-y.

29. Noordman BJ, Spaander MCW, Valkema R, Wijnhoven BPL, van Berge Henegouwen MI, Shapiro J, et al. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018;19:965–74. https://doi.org/10.1016/S1470-2045(18)30201-8.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.